Table 1.
asMIP targets
| Gene | tissue specificity | con1 | alt2 | total |
|---|---|---|---|---|
| CAMK2D* | neural | 8 (4) | 5 (5) | 13 (9) |
| CLTB* | neural | 3 (3) | 3 (3) | 6 (6) |
| EHBP1* | neural | 8 (3) | 4 (4) | 12 (7) |
| ERC1* | neural | 8 (4) | 10 (10) | 18 (14) |
| FEZ2* | neural | 2 (2) | 9 (9) | 11 (11) |
| MARK4 | neural | 8 | 3 | 11 |
| MINK1 | neural | 11 | 10 | 21 |
| MLLT4 | neural | 9 | 10 | 19 |
| MYH10 | neural | 15 | 8 | 23 |
| MYO6 | neural | 10 | 6 | 16 |
| TPD52 | neural | 3 | 6 | 9 |
| TPM1 | muscle | 5 | 7 | 12 |
| TPM2 | muscle | 5 | 6 | 11 |
| TPM3 | muscle | 4 | 6 | 10 |
| ACTB | control | 5 | 0 | 5 |
| GAPDH | control | 8 | 0 | 8 |
| TUBA1B | control | 3 | 0 | 3 |
| totals: | 115 | 93 | 208 | |
Numbers in parentheses correspond to total junctions analyzed by qPCR.
1 The number of predicted constitutive exon junctions targeted by asMIPs indentified from RefSeq [21].
2 The number of potentially alternatively spliced exon junctions targeted identified from RefSeq [21], of which 58 were confirmed in the literature to be alternatively spliced in the tissues we studied [10,20].
* Genes that were assayed with both asMIPs and qPCR.